Emerging Molecular Targets and Recent Advancements for the Management of Depression

Depression is a serious mental disorder characterized by alteration in mood, loss of interest and feeling sad, irritable, and empty. World Health Organization ranks depression as the leading cause of mental disability and is projected to become top contributor to the global disease burden by 2030. The pathogenesis of depression is very diverse, complicated, and unclear. Despite improvements in the conventional treatments, currently available options have shortfalls such as reduced efficacy, increased side effects, not suitable for prolonged usage, patient variance, resistance issues, etc. persists, which emphasize the need of exploring the emerging molecular targets. Recent research advances in neurobiology have highlighted the role of interconnected molecular targets and cellular pathways, including neural circuits, synaptic plasticity, neurotransmitter systems, and HPA axis dysregulation, in depression. These targets regulate key signaling pathways such as PI3K/Akt/mTOR, Ras-MAPK/ERK, and NF-κB, providing promising avenues for the development of novel targeted antidepressant therapies and driving a shift beyond conventional treatment strategies.This review summarizes the emerging molecular targets and recent therapeutic advancements in depression, with a prime focus on their underlying mechanisms, signaling pathways, and clinical significance. Furthermore, recent clinical successes and USFDA-approved targeted antidepressants are discussed, highlighting the growing importance of molecularly guided approaches in antidepressant drug discovery. A deeper understanding of these targets may facilitate the development of safer, more effective therapies for the management of depression in future.